Document Detail


Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study.
MedLine Citation:
PMID:  21123825     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Extranodal NK/T-cell lymphoma, nasal type, is a rare and highly aggressive disease with a grim prognosis. No therapeutic strategy is currently identified in relapsing patients. We report the results of a French prospective phase II trial of an L-asparaginase-containing regimen in 19 patients with relapsed or refractory disease treated in 13 centers. Eleven patients were in relapse and 8 patients were refractory to their first line of treatment. L-Asparaginase-based treatment yielded objective responses in 14 of the 18 evaluable patients after 3 cycles. Eleven patients entered complete remission (61%), and only 4 of them relapsed. The median overall survival time was 1 year, with a median response duration of 12 months. The main adverse events were hepatitis, cytopenia, and allergy. The absence of antiasparaginase antibodies and the disappearance of Epstein-Barr virus serum DNA were significantly associated with a better outcome. These data confirm the excellent activity of L-asparaginase-containing regimens in extranodal NK/T-cell lymphoma. L-Asparaginase-based treatment should thus be considered for salvage therapy, especially in patients with disseminated disease. First-line L-asparaginase combination therapy for extranodal NK/T-cell lymphoma warrants evaluation in prospective trials. This trial is registered at www.clinicaltrials.gov as #NCT00283985.
Authors:
Arnaud Jaccard; Nathalie Gachard; Benoit Marin; Sylvie Rogez; Marie Audrain; Felipe Suarez; Hervé Tilly; Franck Morschhauser; Catherine Thieblemont; Loic Ysebaert; Alain Devidas; Barbara Petit; Laurence de Leval; Philippe Gaulard; Jean Feuillard; Dominique Bordessoule; Olivier Hermine;
Related Documents :
21148615 - Approval summary: pemetrexed maintenance therapy of advanced/metastatic nonsquamous, no...
2161175 - Spinal cord toxicity complicating treatment with cisplatin and etoposide.
2993535 - High-dose cisplatin in hypertonic saline in refractory ovarian cancer.
21431095 - Clinical impact of tumor regression grade after preoperative chemoradiation for locally...
8200375 - A long-term evaluation of the cin-lesions. a clinicopathological study.
2720605 - Cancer of the breast in poor black women.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-12-01
Journal Detail:
Title:  Blood     Volume:  117     ISSN:  1528-0020     ISO Abbreviation:  Blood     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-02-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7603509     Medline TA:  Blood     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1834-9     Citation Subset:  AIM; IM    
Affiliation:
Service d'Hématologie et de Thérapie Cellulaire, Centre Hospitalier Universitaire (CHU) Limoges, Université et Centre National de la Recherche Scientifique (CNRS), Unité Mixte de Recherche (UMR) 6101, Limoges, France. arnaud.jaccard@chu-limoges.fr
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT00283985
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Investigator
Investigator/Affiliation:
Lionel Galicier / ; Pauline Brice / ; Jean-Baptiste Golfier / ; Christian Gisselbrecht / ; Bertrand Joly / ; Olivier Fitoussi / ; Paul Coppo / ; Bernadette Corront / ; Isabelle Cumin / ; Jean-François Rossi / ; Valérie Coiteux / ; Pascal Lenain / ; Guy Laurent / ; Christian Recher / ; Mathilde Hunault / ; Noel Milpied / ; Kamal Bouabdallah / ; Thibault Legay / ; Stephane Girault / ; Pascal Turlure / ; Natacha Dmytruck / ; Stephane Moreau / ; Marie-Pierre Gourin / ; Mohamed Touati / ; Liliane Remenieras /

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chap...
Next Document:  SYK regulates B-cell migration by phosphorylation of the F-actin interacting protein SWAP-70.